

Asst. Prof. Mustafa Murat ÖZBALAK

Personal Information

Email: mozbalak@istanbul.edu.tr

Web: <http://aves.istanbul.edu.tr/4931/>

Address: Kartaltepe Mah. Necmeddin Sadak Sok. No:6 Tan Apt. Kat:4 Daire:12 Bakırköy/İSTANBUL

International Researcher IDs

ORCID: 0000-0002-3040-4052

Publons / Web Of Science ResearcherID: AAU-8100-2020

Yoksis Researcher ID: 176894

Biography

Murat Ozbalak, M.D., was born in 1984 in Istanbul. Following his primary education in F.M.V. Ozel Işık Primary School, he finished highschool in Galatasaray Highschool. He was graduated from Istanbul University Cerrahpasa Medical Faculty English Program in 2009. He completed his residency in Istanbul University Cerrahpasa Medical Faculty in 2015. He worked in Batman Kozluk State Hospital between November 2015 and April 2017 and then, in Istanbul Bahcelievler State Hospital until February 2018. He is Hematology fellow in Istanbul Medical Faculty since June 2018. He is a PhD candidate in the Immunology Department of Aziz Sancar Experimental Medicine Institute.

Education Information

Doctorate, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Immunology, Turkey 2018 - Continues

Post Doctorate of Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 2018 - 2021

Expertise In Medicine, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine, Turkey 2010 - 2015

Undergraduate, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, English Education Program, Turkey 2003 - 2009

Foreign Languages

English, C1 Advanced

French, C1 Advanced

Italian, A1 Beginner

Dissertations

Expertise In Medicine, Killer Immunoglobuline Like Receptor gene analysis in Chronic Lymphocytic Leukemia and its relation with autoimmunity, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine, 2015

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Hematology, Immunology and Rheumatology

Academic Titles / Tasks

Specialization Student, Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , 2018 - 2021

Specialization Student, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine, 2010 - 2015

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Sequencing novel agents in the treatment of classical hodgkin lymphoma.**
Ferhanoglu B., Özbalak M. M.
Expert review of hematology, 2023 (SCI-Expanded)
- II. **Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data**
Atesoglu E. B., Gulbas Z., UZAY A., ÖZCAN M., ÖZKALEMKAŞ F., Dal M. S., Kalyon H., Akay O. M., Deveci B., Bekoz H., et al.
HEMATOLOGICAL ONCOLOGY, vol.41, no.4, pp.663-673, 2023 (SCI-Expanded)
- III. **Independent risk factors for COVID-19-associated coagulopathy.**
Tor Y., Ozbalak M. M., Kalayoglu-Besisik S., Aksoy E., Cagatay A., Gul A., Erelel M., Senkal N., Medetalibeyoglu A., Kose M., et al.
European review for medical and pharmacological sciences, vol.27, no.16, pp.7851-7860, 2023 (SCI-Expanded)
- IV. **Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience**
Özbalak M. M., Güzel Mastanzade M., Özlük Ö., Tiryaki T. O., Erdem S., Özbalak E. P., Elverdi T., Yönel Hindilerden İ., Altay A. Y., Yeğen G., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.39, no.4, pp.254-261, 2022 (SCI-Expanded)
- V. **Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series**
Bayrak A. G., Daglar Aday A., Yavuz A. S., Nalcaci M., Ozbalak M. M., Cefle K., Ozturk Ş., Palanduz Ş.
LEUKEMIA RESEARCH, vol.111, 2021 (SCI-Expanded)
- VI. **Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.**
Akay O. M., Ozbalak M. M., Pehlivan M., Yildiz B., Uzay A., Yigenoglu T. N., Elverdi T., Kaynar L., Ayyildiz O., Yonal Hindilerden I., et al.
Hematological oncology, vol.39, no.4, pp.498-505, 2021 (SCI-Expanded)
- VII. **Raman tweezers as an alternative diagnostic tool for paroxysmal nocturnal hemoglobinuria.**
Soysal K. B., Parlattan S., Mastanzade M., Ozbalak M. M., Yenerel M. N., ÜNLÜ M. B., Başar G., Parlattan U.
Analytical methods : advancing methods and applications, vol.13, no.35, pp.3963-3969, 2021 (SCI-Expanded)
- VIII. **Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study**
Ozbalak M. M., Akay O. M., PEHLİVAN M., Yildiz B., UZAY A., Yigenoglu T. N., ELVERDİ T., KAYNAR L., Ayyildiz O., Hindilerden I. Y., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, 2021 (SCI-Expanded)
- IX. **Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience**
Bekoz H., ÖZBALAK M. M., Karadurmus N., PAYDAŞ S., Turker A., TOPTAŞ T., Tuglular T. F., Altuntas F., Cakar M. K., SÖNMEZ M., et al.
ANNALS OF HEMATOLOGY, vol.99, no.11, pp.2565-2576, 2020 (SCI-Expanded)
- X. **Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.**

Ozbalak M. M., SALİHOĞLU A., Soysal T., Karadogan I., PAYDAŞ S., Ozdemir E., Yildiz B., Karadurmus N., KAYNAR L., Yagci M., et al.

Annals of hematology, vol.99, no.2, pp.301-307, 2020 (SCI-Expanded)

- XI. **Venetoclax-Rituximab in Chronic Lymphocytic Leukemia**
Ferhanoglu B., Ozturk E., ÖZBALAK M. M.
NEW ENGLAND JOURNAL OF MEDICINE, vol.378, no.22, pp.2141-2143, 2018 (SCI-Expanded)
- XII. **Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.**
Bekoz H., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T. F., Sonmez M., Gulbas Z., Tekgunduz E., Kaya A. H., et al.
Annals of oncology : official journal of the European Society for Medical Oncology, vol.28, no.10, pp.2496-2502, 2017 (SCI-Expanded)
- XIII. **Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma**
Falay O., Ozturk E., Bolukbasi Y., Gumus T., Ornek S., ÖZBALAK M. M., Cetiner M., Demirkol O., Ferhanoglu B.
LEUKEMIA & LYMPHOMA, vol.58, no.5, pp.1114-1122, 2017 (SCI-Expanded)
- XIV. **Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.**
ÖZTÜRK E., ÖZBALAK M. M., Berk S., Erdoğan I., AVŞAR E., DOLGUN A., ÇETİNER M., MANDEL N. K., YALNIZ F. F., ELVERDI T., et al.
Leukemia & lymphoma, vol.57, pp.1211-4, 2016 (SCI-Expanded)
- XV. **Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(-) EBV(-) HHV8(+) patient.**
Ozbalak M. M., TOKATLI I., Ozdemirli M., Tecimer T., Ar M. C., ORNEK S., KOROGU A., LALELI Y., FERHANOGLU B.
European journal of haematology, vol.91, no.5, pp.467-9, 2013 (SCI-Expanded)
- XVI. **An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.**
Salihoglu A., Ozbalak M. M., Keskin D., Tecimer T., Soysal T., Ferhanoglu B.
Transplantation proceedings, vol.45, no.7, pp.2845-8, 2013 (SCI-Expanded)
- XVII. **Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.**
Ozbalak M. M., Cetiner M., Bekoz H., Atesoglu E. B., Ar C., Salihoglu A., Tuzuner N., Ferhanoglu B.
Hematological oncology, vol.30, no.2, pp.76-81, 2012 (SCI-Expanded)
- XVIII. **Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases.**
Ar M. C., Ozbalak M. M., Tuzuner N., Bekoz H., Ozer O., Ugurlu K., Tabak F., Ferhanoglu B.
Transplantation proceedings, vol.41, no.5, pp.1648-53, 2009 (SCI-Expanded)
- XIX. **Prognostic significance of micro vessel density in diffuse large B cell lymphomas**
Soer M., Ozbalak M. M., Senocak M., Soysal T., Ferhanoglu B., Molinas N., Tuzuner N.
VIRCHOWS ARCHIV, vol.451, no.2, pp.357-358, 2007 (SCI-Expanded)
- XX. **Primary cutaneous T-cell lymphomas other than mycosis fungoides and primary cutaneous CD30(+) lymphoproliferative disorders**
Ozbalak M. M., Demirkesen C., Oguz O., Onsun N., Tuzuner N.
VIRCHOWS ARCHIV, vol.451, no.2, pp.456, 2007 (SCI-Expanded)

Articles Published in Other Journals

- I. **Central nervous system involvement of mantle cell lymphoma: Case report and review of the literature**
Ağargün B. F., Yegen G., Özbalak M. M., Gülseren Ü. A.
Hematology, Transfusion and Cell Therapy, vol.1, no.1, pp.1, 2022 (ESCI)
- II. **Salvage Intrapartum Splenectomy for the Treatment of Transfusion-refractory Anaemia in a β-**

thalassemia Intermedia Patient

Saraç Sivriköz T., Özbalak M. M., Tükenmez M., Beşışık S.

Journal of College of Physicians and Surgeons Pakistan, vol.32, no.10, pp.1344-1346, 2022 (Peer-Reviewed Journal)

- III. **Dipyridamole does not have any additive effect on the prevention of COVID-19 coagulopathy.**
Kalayoglu Besisik S., Ozbalak M. M., Tor Y. B., Medetalibeyoglu A., Kose M., Senkal N., Cagatay A., Erelel M., Gul A., Esen F., et al.
American journal of blood research, vol.12, no.2, pp.54-59, 2022 (Peer-Reviewed Journal)
- IV. **R-CHOP Chemotherapy with a Rituximab Biosimilar (Redditux®) for Patients with de novo Diffuse Large B-cell Lymphoma: First Preliminary Results of a Real-Life Single-Center Experience from Turkey**
Özbalak M. M., Mastanzade M., Özlük Ö., Tiryaki T. O., Pınar Özbalak E., Yönel Hindilerden İ., Altay A. Y., Yegen G., Yenerel M. N., Nalçacı M., et al.
İstanbul Kanuni Sultan Süleyman Tıp Dergisi , vol.13, no.3, pp.194-198, 2021 (Peer-Reviewed Journal)
- V. **KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY**
Ozbalak M. M., Ozunal I. E., Berk S., ELVERDİ T., SALİHOĞLU A., EŞKAZAN A. E., Ozbalak E. P., Cem A. R., ÖNGÖREN Ş., BAŞLAR Z., et al.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGISİ, vol.84, no.2, pp.227-236, 2021 (ESCI)
- VI. **Initial complete blood count score and predicting disease progression in COVID-19 patients.**
Ozbalak M. M., Kalayoglu Besisik S., Tor Y. B., Medetalibeyoglu A., Kose M., Senkal N., Aksoy E., Cagatay A., Erelel M., Gul A., et al.
American journal of blood research, vol.11, no.1, pp.77-83, 2021 (ESCI)
- VII. **Cytomegalovirus reactivation during adult acute lymphoblastic leukemia maintenance: do we underestimate (un)expected guest of pediatric approach?**
Ozbalak M. M., Mastanzade M., GÜREL E., BEŞİŞİK S.
AMERICAN JOURNAL OF BLOOD RESEARCH, vol.11, no.1, pp.118-122, 2021 (ESCI)
- VIII. **Initial complete blood count score and predicting disease progression in COVID-19 patients**
Ozbalak M. M., Besisik S., Tor Y. B., Medetalibeyoglu A., Kose M., Senkal N., Aksoy E., Cagatay A., Erelel M., Gül A., et al.
AMERICAN JOURNAL OF BLOOD RESEARCH, vol.11, no.1, pp.77-83, 2021 (ESCI)
- IX. **Retrospective Analysis of Peripheral T-Cell Lymphoma Patients: Single Center 'Real-Life' Experience**
Beşışık S., Özbalak M. M., Mastanzade M.
Medical Journal of Bakirkoy, vol.16, no.4, pp.1-7, 2020 (ESCI)
- X. **Gıda Kaynaklı İmmünomodulatorler**
Kohansal Koshksaray F., Özbalak M. M., Balkan İ. İ., Erten Yurdağül G.
Experimed, vol.10, no.2, pp.97-111, 2020 (Peer-Reviewed Journal)
- XI. **Bortezomib induced pulmonary toxicity: a case report and review of the literature**
Saglam B., Kalyon H., Ozbalak M. M., Ornek S., Keske S., Tabak L., Cakar N., Zeren H. N., Aytekin S., Bolukbasi Y., et al.
AMERICAN JOURNAL OF BLOOD RESEARCH, vol.10, no.6, pp.407-415, 2020 (ESCI)
- XII. **Retrospective Analysis of Peripheral T-Cell Lymphoma Patients: Single Center 'Real-Life' Experience**
Ozbalak M. M., MASTANZADE M., Ozluk O., TIRYAKI T. O., Hindilerden I. Y., YENEREL M. N., ALTAY A. Y., YEGEN G., Dogan I. O., NALÇACI M., et al.
MEDICAL JOURNAL OF BAKIRKOY, vol.16, no.4, pp.392-398, 2020 (ESCI)
- XIII. **Inflammatory myofibroblastic tumor mimicking a relapse in a patient with Hodgkin's lymphoma: report of an unusual case and review of the literature.**
Özbalak M. M., Torun E. S., ÖZDEMİRLİ M., Uçar A. R., Akpınar T. S., Taşcıoğlu C., Ferhanoğlu B.
Clinical case reports, vol.5, pp.945-949, 2017 (ESCI)
- XIV. **Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study.**
Ozbalak M. M., Ar M. C., Tuzuner N., Salihoglu A., Eskazan A. E., Ongoren Aydin S., Baslar Z., Soysal T., Aydin Y., Barak Dolgun A., et al.

Refereed Congress / Symposium Publications in Proceedings

- I. **Büyük granüllü lenfosit artışı olan olguların tanısında immünfenotiplemenin rolü: Tek merkez deneyimi**
NAZLIGÜL SERT E., TİRYAKİ T. O., ÖZBALAK M. M., MASTANZADE M., ÖZLÜK D. Ö., ERDEM S., YÖNAL HİNDİLERDEN İ., BEŞİŞİK S., NALÇACI M., YENEREL M. N.
48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 01 November 2022, pp.199-200
- II. **Kronik lenfosit lösemi olgularının tanı sırasındaki T lenfosit alt gruplarının prognoz üzerine etkisi**
SEYİTHANOĞLU D., NAZLIGÜL SERT E., ERDEM S., ÖZBALAK M. M., MASTANZADE M., ÖZLÜK D. Ö., TİRYAKİ T. O., BEŞİŞİK S., NALÇACI M., YENEREL M. N.
48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 01 November 2022, pp.145-146
- III. **Multipl miyelom dışı plazma hücre hastalıklarında kök hücre desteği ile yüksek doz kemoterapi deneyimi**
TİRYAKİ T. O., YÖNAL HİNDİLERDEN İ., ERDEM S., MASTANZADE M., ÖZBALAK M. M., OLUK B., SAKCI E., TAGHİYEVA N., İBİLİ ÇETİNKAYA N. S., YENEREL M. N., et al.
48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 01 November 2022, pp.196-197
- IV. **ASPARAGINASE INDUCED SINUS VEIN THROMBOSIS IN AN ADULT YOUNG ALL PATIENT**
OLUK B., KUBİLAY D. Ö., ÖZBALAK M. M., ERDEM S., BEŞİŞİK S.
XIIth Eurasian Hematology-Oncology Congress, İSTANBUL (Hibrit Kongre), Turkey, 10 November 2021, vol.43, pp.77
- V. **WHAT HAVE WE EXPERIENCED WITH COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISORDERS?**
ERDEM S., MASTANZADE M., ÖZBALAK M. M., KUBİLAY D. Ö., TİRYAKİ T. O., OLUK B., YÖNAL HİNDİLERDEN İ., YENEREL M. N., NALÇACI M., BEŞİŞİK S., et al.
XIIth Eurasian Hematology-Oncology Congress, İSTANBUL (Hibrit Kongre), Turkey, 10 November 2021, vol.43, pp.96
- VI. **Yeni tanı DBBHL'de biyobenzer rituksimab (Redditux) içeren R-CHOP rejimi sonuçları: Tek merkez gerçek yaşam deneyimi**
ÖZBALAK M. M., MASTANZADE M., KUBİLAY D. Ö., TİRYAKİ T. O., ERDEM S., Pınar Özbalak E., ELVERDİ T., YÖNAL HİNDİLERDEN İ., YENEREL M. N., SOYSAL T., et al.
47. Ulusal Hematoloji Kongresi, Antalya, Turkey, 04 November 2021
- VII. **A Case of Congenital Afibrinogenemia with Two Successful Spontaneous Delivery after Recurrent Pregnancy Losses**
Mastanzade M., Özbalak M. M., Beşişik S.
ISTH 2021 Congress, Pennsylvania, United States Of America, 17 - 21 July 2021, no.5, pp.312
- VIII. **Increased activity of follicular helper T and cytotoxic T cells in chronic lymphocytic leukemia**
Gelmez M. Y., Öktelek F. B., Çınar S., Özbalak M. M., Deniz G.
6th European Congress of Immunology (ECI 2021), Belgrade, Serbia, 1 September - 04 October 2021, pp.1
- IX. **Increased activity of follicular helper T and follicular cytotoxic T cells in Chronic Lymphocytic Leukemia**
Gelmez M. Y., Öktelek F. B., Çınar S., Özbalak M. M., Özlük Ö., Deniz G., Aktan M.
6th European Congress of Immunology, Belgrade, Serbia, 1 - 04 September 2021, pp.245
- X. **Dual-Beam optical Manipulation of Red blood cells for the investigation of paroxysmal nocturnal hemoglobinuria**
Parlatan U., Soysal K. B., Parlatan S., Mastanzade M., Özbalak M. M., Yenerel M. N., Unlu B.
Optical Manipulation and Its Applications, OMA 2021 - Part of Biophotonics Congress: Optics in the Life Sciences 2021, Virtual, Online, United States Of America, 12 - 16 April 2021
- XI. **A raman tweezer study with single red blood cells for the diagnosis of paroxysmal nocturnal hemoglobinuria**

Parlatan S., Parlatan U., Soysal K. B., Mastanzade M., Ozbalak M. M., Yenerel M. N., Başar G., Unlu B.
Optical Molecular Probes, Imaging and Drug Delivery, OMP 2021 - Part of Biophotonics Congress: Optics in the Life Sciences 2021, Virtual, Online, United States Of America, 12 - 16 April 2021

- XII. **Prognostic value of pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratio in diffuse large B-cell lymphoma: a single-center experience**
Dağcı G., Mastanzade M., Özbalak M. M., Kubilay D. Ö., Tiryaki T. O., Yönel Hindilerden İ., Yenerel M. N., Nalçacı M., Beşışık S.
XIth Eurasian Hematology Oncology Congress, İstanbul, Turkey, 21 - 24 October 2020, no.42, pp.48-49
- XIII. **FUSARIUM SPP İLE SİNÖPULMONER İNFEKSİYON: HEMATOLOJİK MALİGNİTELERDE İKİNCİ SIKLIKTA KÜF MANTARI İNFEKSİYONU**
ÖZLÜK SEVEN Ö., OLUK B., ÖZBALAK M. M., SOLTANOVA L., ALTUNOK D., YILMAZ E., KESKİN SARITAŞ Ç., AYDEMİR L., VURALLI BAKKALOĞLU D., BEŞİŞİK S.
46. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 28 - 31 October 2020, pp.177-178
- XIV. **Role of [68Ga]-pentixafor-PET/CT as a novel imaging of cxcr4 expression in multiple myeloma comparison to [18F]-FDG-PET/CT**
TİRYAKİ T. O., KUYUMCU S., HAS ŞİMŞEK D., ÖZBALAK M. M., KUBİLAY D. Ö., ÜNAL S. N., BEŞİŞİK S.
Xth International Eurasian Hematology-Oncology Congress, İstanbul, Turkey, 8 - 12 October 2019, vol.85
- XV. **A relapsed refractory CD30 positive cutaneous anaplastic large cell lymphoma with large B-cell transformation responding to brentuximab vedotin after multiple lines of treatment**
Erdem S., Ozbalak M. M., Baykal C., Besisik S.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85
- XVI. **Role of [Ga-68]-pentixafor-PET/CT as a novel imaging of cxcr4 expression in multiple myeloma; comparison to [F-18]-FDG-PET/CT**
Tiryaki T. O., Kuyumcu S., Has-Simsek D., Ozbalak M. M., Ozluk D., Unal S., Kalayoglu-Besisik S.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85
- XVII. **A retrospective analysis of peripheral T-cell lymphoma patients: single-center 'real-life' experience**
Ozbalak M. M., Besisik S., Mastanzade M., Ozluk O., Ozmen A., Hindilerden I. Y., Yenerel M. N., Nalcaci M.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85
- XVIII. **Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience**
Ferhanoglu A. B., ÖZBALAK M. M., SALİHOĞLU A., Soysal T., Karadogan I., Paydas S., Ozdemir E., Yildiz B., Karadurmus N., KAYNAR L., et al.
59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130
- XIX. **NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY**
Ferhanoglu B., Bekoz H., Karadurmus N., Paydas S., Gulbas Z., Turker A., Toptas T., Tuglular T. F., Tekgunduz E., Kaya A. H., et al.
22nd Congress of the European-Hematology-Association, Madrid, Spain, 22 - 25 June 2017, vol.102, pp.84-85
- XX. **IS FDG-PET THE MOST SENSITIVE TOOL TO DIAGNOSE BLEOMYCIN INDUCED PNEUMONITIS IN HODGKIN'S LYMPHOMA?**
Ozturk E., Falay O., Bolukbasi Y., Gumu T., Ornek S., ÖZBALAK M. M., Demirkol O., Ferhanoglu B.
10th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22 - 25 October 2016, vol.101, pp.43
- XXI. **The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis.**
Ozturk M., Ozaydin S., Oyan B., Ozbalak M. M., Arpacı F., Paydas S., Ataergin S., Ferhanoglu B., Kocak N., Gurkan E., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

Metrics

Publication: 55

Citation (WoS): 155

Citation (Scopus): 148

H-Index (WoS): 7

H-Index (Scopus): 6